Menarini extends febuxostat accord to more regions

12 April 2012

Japanese drugmaker Teijin Pharma and privately-owned Italian pharmaceutical company Menarini have signed an exclusive distributorship agreement for the marketing of febuxostat, a novel drug developed by Teijin for the treatment of hyperuricemia and gout, in Central and South America, the Commonwealth of Independent States (CIS) and Oceania. Financial terms of the accord were not disclosed.

Menarini has been marketing febuxostat as Adenuric in Europe since March 2010 under marketing rights granted by licensee French drugmaker Ipsen, which earned the latter an upfront fee of 132 million euros ($172.4 million at current exchange rates; The Pharma Letter October 20, 2009). Japanese drug major Astellas has rights to the drug in most of Asia and also India.

Gets rights in 26 new markets

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical